Overview
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
Status:
Completed
Completed
Trial end date:
2009-09-01
2009-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La Roche
Criteria
Inclusion Criteria:- adult patients, 18-70 years of age;
- medically stable, moderate to severe chronic plaque psoriasis.
Exclusion Criteria:
- any skin condition which may interfere with evaluation of the effect of study
medication on plaque lesions;
- confounding or concomitant condition or treatment.